Filaminast
Clinical data
ATC code
  • None
Legal status
Legal status
  • Development terminated
Identifiers
  • [(E)-1-(3-Cyclopentyloxy-4-methoxyphenyl)ethylideneamino] carbamate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC15H20N2O4
Molar mass292.335 g·mol−1
3D model (JSmol)
  • CC(=NOC(=O)N)C1=CC(=C(C=C1)OC)OC2CCCC2

Filaminast (code name WAY-PDA 641)[1] was a drug candidate developed by Wyeth-Ayerst.[2]: Table 2  It is a phosphodiesterase 4 inhibitor (PDE4 inhibitor) and an analog of rolipram, which served as a prototype molecule for several development efforts.[3][4]: 668, 678  It was discontinued after a Phase II trial showed that its therapeutic window was too narrow; it could not be dosed high enough without causing significant side effects (nausea and vomiting), which was a problem with the rolipram class of molecules.[4]: 678 

See also

References

  1. ^ "Filaminist entry". Pubchem.
  2. ^ Halpin DM (2008). "ABCD of the phosphodiesterase family: interaction and differential activity in COPD". International Journal of Chronic Obstructive Pulmonary Disease. 3 (4): 543–61. doi:10.2147/COPD.S1761. PMC 2650605. PMID 19281073.
  3. ^ Giembycz MA (October 2008). "Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?". British Journal of Pharmacology. 155 (3): 288–90. doi:10.1038/bjp.2008.297. PMC 2567889. PMID 18660832.
  4. ^ a b McKenna JM, Muller GW (5 December 2006). "Medicinal Chemistry of PDE4 Inhibitors. Chapter 33". In Beavo JA, Francis SH, Houslay MD (eds.). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press. ISBN 978-1-4200-2084-7.
Categories